{"id":"investigational-tiv-hd2","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Low-grade fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TIV-HD2 contains higher antigen content compared to standard-dose influenza vaccines, intended to elicit a stronger and more durable immune response. This formulation is particularly targeted at improving vaccine efficacy in populations with reduced immune responsiveness, such as elderly individuals or immunocompromised patients.","oneSentence":"TIV-HD2 is a high-dose trivalent inactivated influenza vaccine designed to provide enhanced immune protection against seasonal influenza.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:47.008Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of seasonal influenza in adults, particularly elderly or immunocompromised populations"}]},"trialDetails":[{"nctId":"NCT03282240","phase":"PHASE3","title":"Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-09-08","conditions":"Influenza","enrollment":2670},{"nctId":"NCT02553343","phase":"PHASE2","title":"A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-09","conditions":"Influenza","enrollment":792}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["High-dose trivalent influenza vaccine (alternate B strain)"],"phase":"phase_3","status":"active","brandName":"Investigational TIV-HD2","genericName":"Investigational TIV-HD2","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"TIV-HD2 is a high-dose trivalent inactivated influenza vaccine designed to provide enhanced immune protection against seasonal influenza. Used for Prevention of seasonal influenza in adults, particularly elderly or immunocompromised populations.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}